Lanfear Dennis M

President & CEO, DirectorCoherus Oncology, Inc. (CHRS) · full profile →Form 4 · filed Jun 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
18
0 non-derivative · 18 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 29, 2026Disposed to issuer(D)200K0
May 29, 2026Disposed to issuer(D)400K0
May 29, 2026Disposed to issuer(D)450K0
May 29, 2026Disposed to issuer(D)500K0
May 29, 2026Disposed to issuer(D)500K0
May 29, 2026Disposed to issuer(D)125K0
May 29, 2026Disposed to issuer(D)403K0
May 29, 2026Disposed to issuer(D)403K0
May 29, 2026Disposed to issuer(D)225K0
May 29, 2026Grant(A)200K200K
May 29, 2026Grant(A)400K400K
May 29, 2026Grant(A)450K450K
May 29, 2026Grant(A)500K500K
May 29, 2026Grant(A)500K500K
May 29, 2026Grant(A)125K125K
May 29, 2026Grant(A)403K403K
May 29, 2026Grant(A)403K403K
May 29, 2026Grant(A)225K225K

Transaction Codes

D
Disposition to the issuer
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-069621) within minutes of acceptance. Every field above traces to the original document. Verify it directly: